Skip to main content
Premium Trial:

Request an Annual Quote

CEO Loans Pressure BioSciences $100K

NEW YORK (GenomeWeb News) – Pressure BioSciences has received a $100,000 loan from its CEO, the company disclosed in a document filed with the US Securities and Exchange Commission today.

The loan from Richard Schumacher has a maturity date of Nov. 5 and can be extended by mutual agreement of both parties. It carries an annual interest rate of 20 percent.

In connection with the loan, Pressure Bio issued Schumacher a warrant to purchase 12,048 shares of the company's stock at an exercise price of $.83 per share. The warrant expires on Sept. 7, 2014.

The company also said that on Sept. 2 it issued an aggregate of 124,996 shares of its common stock to its independent directors in payment for all board fees. The number of shares issued was based on $.84 per share, which was the greater of the consolidated bid or the closing price of Pressure Bio's stock on Sept. 1.

Last month, the South Easton, Mass.-based firm said that its second-quarter revenues dropped 53 percent year over year and that it had enough capital to last only until the middle of September. Earlier this week it received a $161,000 SBIR grant from the National Institute of General Medical Sciences.

The Scan

Booster for At-Risk

The New York Times reports that the US Food and Drug Administration has authorized a third dose of the Pfizer-BioNTech SARS-CoV-2 vaccine for people over 65 or at increased risk.

Preprints OK to Mention Again

Nature News reports the Australian Research Council has changed its new policy and now allows preprints to be cited in grant applications.

Hundreds of Millions More to Share

The US plans to purchase and donate 500 million additional SARS-CoV-2 vaccine doses, according to the Washington Post.

Nature Papers Examine Molecular Program Differences Influencing Neural Cells, Population History of Polynesia

In Nature this week: changes in molecular program during embryonic development leads to different neural cell types, and more.